The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

The invention relates to a marking precursor incorporating a chelator or fluorination group for radiolabelling with .sup.44Sc, .sup.47Sc, .sup.55Co, .sup.62Cu, .sup.64Cu, .sup.67Cu, .sup.66Ga, .sup.67Ga, .sup.68Ga, .sup.89Zr, .sup.86Y, .sup.90Y, .sup.90Nb, .sup.99mTc, .sup.111In, .sup.135Sm, .sup.140Pr, .sup.159Gd, .sup.149Tb, .sup.160Tb, .sup.161Tb, .sup.165Er, .sup.166Dy, .sup.166Ho, .sup.175Yb, .sup.177Lu, .sup.186Re, .sup.188Re, .sup.213Bi and .sup.225Ac or with .sup.18F, .sup.131I or .sup.211At, and one or two biological targeting vectors which are coupled to the chelator or fluorinating group via one or more squaric acid groups.

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Provided is an ionic liquid including a cationic compound represented by Formula (1), where R represents an N-containing heterocyclic cation, and an anionic compound, an electrolyte including the ionic liquid, and a secondary battery.

##STR00001##

Provided is an ionic liquid including a cationic compound represented by Formula (1), where R represents an N-containing heterocyclic cation, and an anionic compound, an electrolyte including the ionic liquid, and a secondary battery.

##STR00001##

The present invention provides compounds, compositions thereof, and methods of using the same.

A compound of formula (I) is:

##STR00001##

wherein: X.sup.2 represents a —CO—NR.sub.k— group, a —NR′.sub.k—CO— group, a —O— group, a —CO— group, a —SO.sub.2-group, a —CS—NH— group, a —CH.sub.2—NH—, a

##STR00002##

group, or a heterocyclyl, wherein the heterocyclyl is a 5- or 6-membered ring comprising 1, 2, 3 or 4 heteroatoms selected from O, S and/or N; Y.sup.2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a morpholinyl group, optionally substituted by a (C.sub.1-C.sub.4)alkyl group or a trifluoromethyl group, a bridged morpholinyl group, a (C.sub.5-C.sub.11)bicycloalkyl group, an adamantyl group, a piperidinyl group, a (C.sub.1-C.sub.4)alkenyl group, a —PO(OR.sub.a)(OR.sub.b) group, a 5-membered heteroaromatic ring or a —CR.sup.1R.sup.2R.sup.3 group, or any of its pharmaceutically acceptable salt.

A compound of formula (I) is:

##STR00001##

wherein: X.sup.2 represents a —CO—NR.sub.k— group, a —NR′.sub.k—CO— group, a —O— group, a —CO— group, a —SO.sub.2-group, a —CS—NH— group, a —CH.sub.2—NH—, a

##STR00002##

group, or a heterocyclyl, wherein the heterocyclyl is a 5- or 6-membered ring comprising 1, 2, 3 or 4 heteroatoms selected from O, S and/or N; Y.sup.2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a morpholinyl group, optionally substituted by a (C.sub.1-C.sub.4)alkyl group or a trifluoromethyl group, a bridged morpholinyl group, a (C.sub.5-C.sub.11)bicycloalkyl group, an adamantyl group, a piperidinyl group, a (C.sub.1-C.sub.4)alkenyl group, a —PO(OR.sub.a)(OR.sub.b) group, a 5-membered heteroaromatic ring or a —CR.sup.1R.sup.2R.sup.3 group, or any of its pharmaceutically acceptable salt.

The present invention relates to a ligand compound, a catalyst system for olefin oligomerization, and a method for olefin oligomerization using the same. The present ligand compound is a compound having a certain new structure and enables provision of a catalyst system for olefin oligomerization that can oligomerize ethylene with higher catalytic activity.